Detalles de la búsqueda
1.
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.
In Vivo;
36(4): 1615-1627, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35738590
2.
Identification of VEGF Signaling Inhibition-Induced Glomerular Injury in Rats through Site-Specific Urinary Biomarkers.
Int J Mol Sci;
22(23)2021 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34884436
3.
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.
ACS Med Chem Lett;
12(7): 1108-1115, 2021 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34267880
4.
Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
Mol Cancer Ther;
20(10): 1809-1819, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34253595
5.
Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain.
J Med Chem;
63(10): 5585-5623, 2020 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32324999
6.
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Nature;
578(7794): 306-310, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31969702
7.
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Leukemia;
34(6): 1646-1657, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31827241
8.
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.
Bioorg Med Chem Lett;
28(10): 1804-1810, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29678460
9.
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
J Med Chem;
60(20): 8369-8384, 2017 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28949521
10.
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
Mol Cancer Ther;
16(8): 1511-1520, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28468776
11.
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
J Med Chem;
60(9): 3828-3850, 2017 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28368119
12.
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
Cancer Res;
77(11): 2976-2989, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28416490
13.
Methylpyrrole inhibitors of BET bromodomains.
Bioorg Med Chem Lett;
27(10): 2225-2233, 2017 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28268136
14.
HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.
Mol Cancer Ther;
16(2): 388-396, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27903752
15.
Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
Mol Cancer Res;
15(1): 35-44, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27707886
16.
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Invest New Drugs;
33(4): 870-80, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25933833
17.
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Sci Transl Med;
7(279): 279ra40, 2015 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25787766
18.
Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvß3-targeted radiotracer 99mTc-3P-RGD2.
J Pharmacol Exp Ther;
346(2): 251-8, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23750021
19.
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
J Pharmacol Exp Ther;
343(3): 617-27, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22935731
20.
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.
Bioorg Med Chem Lett;
22(14): 4750-5, 2012 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22695126